Authors

Daniel G. Haller, MD,FACP,FRCP, University of Pennsylvania

Daniel G. Haller, MD, University of Pennsylvania

Daniel G. Stover, MD

Latest:

Neoadjuvant and Adjuvant Chemotherapy Considerations for Triple-Negative Breast Cancer

Growing attempts to develop biomarkers to guide therapy within triple-negative breast cancer may lead to more effective regimens or to novel therapeutic targets.

Daniel George, MD

Latest:

Dr George on Other Potential Roles for Radioligand Therapy in Prostate Cancer

Daniel J. George, MD, discusses the potential use of lutetium-177 earlier in the treatment paradigm for metastatic castration-resistant prostate cancer.

Daniel George, MD, Duke Cancer Institute

Daniel H. Ahn, DO

Latest:

Dr. Ahn on the Evolution of First-line Treatment Options in HCC

Daniel H. Ahn, DO, discusses the evolution of first-line treatments in advanced hepatocellular carcinoma.

Daniel H. Ahn, MD

Latest:

Dr. Ahn on Link Between Tumor Somatic Variants and Chemo Resistance in Biliary Tract Cancer

Daniel H. Ahn, MD, assistant professor of Medicine, Mayo Clinic, discusses a next-generation sequencing survey of biliary track cancer to reveal the association between tumor somatic variants and chemotherapy resistance.

Daniel H. Fowler, MD

Latest:

Dr. Fowler on the Mechanism of Action of T-rapa Cells

Daniel H. Fowler, MD, senior investigator, Center for Cancer Research, National Cancer Institute, describes the mechanism of action of T-rapa cells.

Daniel H. Galmarini

Latest:

Daniel H. Galmarini Provides an Overview of Adaptive Radiotherapy

Daniel H. Galmarini, Chief Technology Officer/Director, Physics and Engineering, 21st Century Oncology, provides an overview of adaptive radiotherapy.

Daniel Haraf, MD

Latest:

Dr. Haraf on Induction Chemotherapy With Radiation For Advanced Head and Neck Cancer

Daniel Heng,

Daniel HEng, MD, MPH, FRCPC, Tom Baker Cancer Center

Daniel Hier, MD, MBA

Latest:

Everyone Loves e-Prescribing! Right?

Electronic prescribing is rapidly gaining support from a diverse array of healthcare organizations, government agencies, and technology corporations.

Daniel I. Quinn, MBBS, PhD, FRACP, FACP, University of Southern California

Daniel Indelicato MD

Latest:

Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue Sarcomas

Neoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.

Daniel J. Brat, MD, PhD

Latest:

Dr. Daniel Brat on Characterizing Diffuse Lower Grade Gliomas

Daniel J. Brat, MD, PhD, vice chair, Translational Programs, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, director, Cancer Tissue and Pathology Shared Resource, Winship Cancer Institute, discusses genomic characterization of diffuse lower grade gliomas.

Daniel J. DeAngelo, MD, PhD

Latest:

Dr DeAngelo on the FDA Approval of Obe-Cel in R/R B-Cell Precursor ALL

Daniel DeAngelo, MD, PhD, discusses data supporting the FDA approval of obe-cel for patients with relapsed or refractory B-cell precursor ALL.

Daniel J. DeAngelo, MD, PhD, Dana-Farber Cancer Institute

Latest:

Future Management of Chronic Myeloid Leukemia

Closing out their discussion on the management of chronic myeloid leukemia, experts share practical advice and excitement for novel strategies.

Daniel J. George, MD

Latest:

Dr. George on the Importance of Understanding Mutations in Prostate Cancer

Daniel J. George, MD, discusses the importance of understanding mutations in prostate cancer.

Daniel J. George, MD, Duke